ML104 is a "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.
ML104 affects the viability of breast cancer cell lines and osteoclast precursors, but not osteoblasts in vitro, significantly reduces tumor growth and tumor-associated bone destruction in bone metastatic models (PyMT-R221A and 4T1).
ML104 also decreases multiple myeloma burden and protect against cancer-induced osteolysis, specifically inhibits in the multiple myeloma-bone microenvironment.
